|
|
Volumn 10, Issue 12, 2011, Pages 887-888
|
|
Quarter-century quest for malaria vaccine shows signs of success
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALUMINUM POTASSIUM SULFATE;
FSV 1 VACCINE;
MALARIA VACCINE;
PEPTIDE VACCINE;
PHOSPHORYL LIPID A;
QS 21;
RTSS MALARIA VACCINE;
UNCLASSIFIED DRUG;
ANTIBODY RESPONSE;
ARTICLE;
CELLULAR IMMUNITY;
DISEASE SEVERITY;
DRUG APPROVAL;
DRUG COST;
DRUG EFFICACY;
DRUG FEVER;
DRUG FORMULATION;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TARGETING;
DRUG TOLERABILITY;
DRUG TREATMENT FAILURE;
HIGH RISK POPULATION;
HUMAN;
IMMUNOPHARMACOLOGY;
MALARIA;
MENINGITIS;
MORTALITY;
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PLASMODIUM FALCIPARUM;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
SEIZURE;
VACCINATION;
CLINICAL TRIALS, PHASE III AS TOPIC;
HUMANS;
MALARIA;
MALARIA VACCINES;
|
|
EID: 82455212684
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3611 Document Type: Article |
|
Times cited : (4)
|
|
References (0)
|
